FDA approves new Pfizer and Moderna COVID vaccines

The U.S. Food and Drug Administration (FDA) has approved and authorized updated COVID-19 vaccines for emergency use. These vaccines, developed by Moderna and Pfizer, are designed to better target current variants and provide improved protection against severe COVID-19 outcomes. Key points include:

• Eligibility: Individuals 5 years and older, regardless of prior vaccination, can receive a single dose of the updated vaccine if it has been at least 2 months since their last dose. Children aged 6 months to 4 years can receive one or two doses depending on prior vaccination status. Unvaccinated children in this age group can receive alternative vaccines.
• Safety and Effectiveness: The FDA considers these updated vaccines safe and effective, with benefits outweighing risks.
• Variant Protection: The vaccines are expected to provide strong protection against current variants, with yearly updates possible.
• Recommendations: Official recommendations for vaccination will be discussed, including considerations for specific groups like immunocompromised individuals.

– Availability: The updated vaccines are expected to be available in the near future.

Bivalent vaccines (two-dose versions) from Moderna and Pfizer-BioNTech are no longer authorized. This update emphasizes the importance of vaccination in preventing severe COVID-19 outcomes and adapting to changing virus variants. Specific dosing and eligibility should be verified with healthcare providers and official guidelines.

Source